Drug developers are increasingly focusing on complex protein interaction networks that drive disease, moving beyond single-target biology. Traditional in vitro assays often fail to capture interactions in native intracellular environments, particularly for membrane proteins or variant libraries. This gap has renewed interest in yeast two-hybrid (Y2H) technologies, which Creative Biolabs is advancing through refined platforms.
Creative Biolabs offers a range of two-hybrid services, including yeast two-hybrid (Y2H), mammalian two-hybrid (M2H), bacterial two-hybrid (B2H), and reverse yeast two-hybrid (rYTH), to help clients identify protein-protein interactions in biological systems. To enhance usability, the company has incorporated gateway cloning technology, enabling rapid transfer of DNA sequences into compatible vector systems. "We use gateway cloning technology, which allows us to quickly transfer DNA sequences encoding proteins of interest into different vector systems compatible with the two-hybrid assay, streamlining the setup process," said a scientist at Creative Biolabs.
The improved platforms have already yielded practical benefits. "We were finally able to screen membrane proteins that had stalled our project for months," said a Principal Scientist at a U.S. biotech firm. A Group Leader at a European research institute noted, "The reverse Y2H platform gave us a clean readout on disruptive mutations. It clarified our drug mechanism faster than expected."
Beyond two-hybrid services, Creative Biolabs offers broader discovery services for identifying binders such as antibodies, peptides, or small molecules. The company emphasizes its strengths in binder discovery through precise identification technologies, diverse platforms, customized strategies, and reliable results.
As protein interaction research expands into fields like oncology and synthetic biology, Creative Biolabs views its enhanced platform as part of a shift toward integrated, mechanism-aware discovery tools. "Protein interactions shape nearly every biological process," said a spokesperson for Creative Biolabs. "Our goal is to give researchers technologies that not only generate data but help them understand the story behind that data."
